In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is BD Back on Track?

Executive Summary

BD's top management faced tough questioning at the company's year-end meeting with analysts, following a surprisingly tough year. The company missed its third quarter numbers and ended the year short of expectations. The setbacks, say BD executives, are temporary, and the firm is holding to its goals of 10% top line and 15% eps growth, although not for fiscal year 2000. Growth drivers are new product introductions, the conversion of sharps devices to safety devices, as required by law, and sustained growth in areas such as advanced drug delivery devices and flow cytometry.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts